Evidence map›Paper›PMID 30342588›Full record

ReviewImmunology and allergy clinics of North America2018

Biomarkers in Chronic Rhinosinusitis with Nasal Polyps.

Alan D Workman, Michael A Kohanski, Noam A Cohen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunology and allergy clinics of North America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. The value of biomarkers in the therapy of CRSwNP with biologicals-a long-term follow-up of dupilumab therapy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Immunological Aspects of Chronic Rhinosinusitis.Diagnostics (Basel, Switzerland) · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Alan D WorkmanDepartment of Otorhinolaryngology-Head and Neck Surgery, Division of Rhinology, University of Pennsylvania, Perelman School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Michael A KohanskiDepartment of Otorhinolaryngology-Head and Neck Surgery, Division of Rhinology, University of Pennsylvania, Perelman School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Noam A CohenDepartment of Otorhinolaryngology-Head and Neck Surgery, Division of Rhinology, University of Pennsylvania, Perelman School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA; Philadelphia Veterans Affairs Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104, USA; Monell Chemical Senses Center, 3500 Market Street, Philadelphia, PA 19104, USA. Electronic address: Noam.Cohen@uphs.upenn.edu.
University of Pennsylvania · USVeterans Health Administration · US

Funding

Chronic Rhinosinusitis and genetics of bitter taste receptorsR01DC013588 · NIDCD · UNIVERSITY OF PENNSYLVANIA · PI COHEN, NOAM A · 2014 to 2018
$2.4M
Taste Receptor Genetics, The Sinonasal Microbiome and Chronic RhinosinusitisI01CX001617 · VA · PHILADELPHIA VA MEDICAL CENTER · PI COHEN, NOAM A · 2018 to 2022
–
CSRD VA I01 CX001617NIDCD NIH HHS R01 DC013588
6 · The paper itself

Abstract

Chronic rhinosinusitis is a complex disease that exists along the inflammatory spectrum between types 1 and 2 inflammation. The classic phenotypic differentiation of chronic rhinosinusitis based on the presence or absence of inflammatory polyps remains one of the best differentiators of response to therapy. Development of biologics for the treatment of atopic disease and asthma and topical therapies for sinusitis have placed renewed emphasis on understanding the pathophysiology of polyp disease. Identification of key markers of polyposis will allow for better stratification of inflammatory polyp disease endotypes to objectively identify medical therapies and track response to treatment.

Indexed as

BiomarkersChronic DiseaseHumansNasal PolypsRhinitisSinusitisBiomarkersBiomarkersChronic rhinosinusitisGeneticsMicrobiomePolyps

Identifiers

PMID30342588
PMCPMC6201304
OpenAlexW2891662974

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.